CMS has issued new dedicated HCPCS codes E0743 and A4544 along with payments for Noctrix Health's flagship Nidra TM TOMAC therapy and supplies, respectively, intended to treat symptoms of RLS. The new codes will be effective October 1, 2024 , enabling broader access to this breakthrough therapy for millions of Medicare beneficiaries and patients across the United States . The Nidra TM TOMAC System delivers electrical stimulation to the peroneal nerves via a pair of leg-worn devices.
It is the first and only clinically validated, non-pharmacologic treatment designed to reduce symptoms of RLS and improve sleep quality in adults who do not respond to medication. PLEASANTON, Calif. , Aug.
19, 2024 /PRNewswire/ -- Noctrix Health announced that the Centers for Medicare & Medicaid Services (CMS) have established new reimbursement codes and payment for the company's flagship product, the Nidra TM Tonic Motor Activation (TOMAC) system, the first FDA-cleared wearable medical device to treat symptoms of Restless Legs Syndrome (RLS). This milestone marks a pivotal moment in making this breakthrough therapy accessible to millions of patients suffering from debilitating symptoms of RLS, recognizing the critical need for accessible, non-pharmaceutical treatments. Nidra TM TOMAC therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-p.